fluvoxamine	sulforidazine	1	2	false	none	The effect of fluvoxamine (25 mg b.i.d. for one week) on thioridazine steady-state concentration was evaluated in ten male inpatients with schizophrenia.  Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased 3-fold following coadministration of fluvoxamine.  		42355	none	D016666	C040634
fluvoxamine	sulforidazine	1	2	false	none	The effect of fluvoxamine (25 mg b.i.d. for one week) on thioridazine steady-state concentration was evaluated in ten male inpatients with schizophrenia.  Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased 3-fold following coadministration of fluvoxamine.  		42355	none	D016666	C040634
fluvoxamine	sulforidazine	2	2	false	none	Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased 3-fold following coadministration of fluvoxamine.  		42355	none	D016666	C040634
fluvoxamine	sulforidazine	2	2	false	none	Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased 3-fold following coadministration of fluvoxamine.  		42355	none	D016666	C040634
fluvoxamine	sulforidazine	3	2	false	none	Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased 3-fold following coadministration of fluvoxamine.  Fluvoxamine and thioridazine should not be coadministered.  		42355	none	D016666	C040634
fluvoxamine	sulforidazine	3	2	false	none	Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased 3-fold following coadministration of fluvoxamine.  Fluvoxamine and thioridazine should not be coadministered.  		42355	none	D016666	C040634
fluvoxamine	thioridazine	1	1	false	none	The effect of fluvoxamine (25 mg b.i.d. for one week) on thioridazine steady-state concentration was evaluated in ten male inpatients with schizophrenia.  		42355	10502	D016666	D013881
fluvoxamine	thioridazine	1	1	false	none	The effect of fluvoxamine (25 mg b.i.d. for one week) on thioridazine steady-state concentration was evaluated in ten male inpatients with schizophrenia.  		42355	10502	D016666	D013881
fluvoxamine	thioridazine	1	2	true	positive	The effect of fluvoxamine (25 mg b.i.d. for one week) on thioridazine steady-state concentration was evaluated in ten male inpatients with schizophrenia.  Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased 3-fold following coadministration of fluvoxamine.  		42355	10502	D016666	D013881
fluvoxamine	thioridazine	1	2	true	positive	The effect of fluvoxamine (25 mg b.i.d. for one week) on thioridazine steady-state concentration was evaluated in ten male inpatients with schizophrenia.  Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased 3-fold following coadministration of fluvoxamine.  		42355	10502	D016666	D013881
fluvoxamine	thioridazine	1	3	true	positive	The effect of fluvoxamine (25 mg b.i.d. for one week) on thioridazine steady-state concentration was evaluated in ten male inpatients with schizophrenia.  Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased 3-fold following coadministration of fluvoxamine.  Fluvoxamine and thioridazine should not be coadministered.  		42355	10502	D016666	D013881
fluvoxamine	thioridazine	1	3	true	positive	The effect of fluvoxamine (25 mg b.i.d. for one week) on thioridazine steady-state concentration was evaluated in ten male inpatients with schizophrenia.  Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased 3-fold following coadministration of fluvoxamine.  Fluvoxamine and thioridazine should not be coadministered.  		42355	10502	D016666	D013881
fluvoxamine	thioridazine	2	1	true	positive	The effect of fluvoxamine (25 mg b.i.d. for one week) on thioridazine steady-state concentration was evaluated in ten male inpatients with schizophrenia.  Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased 3-fold following coadministration of fluvoxamine.  		42355	10502	D016666	D013881
fluvoxamine	thioridazine	2	1	true	positive	The effect of fluvoxamine (25 mg b.i.d. for one week) on thioridazine steady-state concentration was evaluated in ten male inpatients with schizophrenia.  Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased 3-fold following coadministration of fluvoxamine.  		42355	10502	D016666	D013881
fluvoxamine	thioridazine	2	2	true	positive	Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased 3-fold following coadministration of fluvoxamine.  		42355	10502	D016666	D013881
fluvoxamine	thioridazine	2	2	true	positive	Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased 3-fold following coadministration of fluvoxamine.  		42355	10502	D016666	D013881
fluvoxamine	thioridazine	2	3	true	positive	Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased 3-fold following coadministration of fluvoxamine.  Fluvoxamine and thioridazine should not be coadministered.  		42355	10502	D016666	D013881
fluvoxamine	thioridazine	2	3	true	positive	Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased 3-fold following coadministration of fluvoxamine.  Fluvoxamine and thioridazine should not be coadministered.  		42355	10502	D016666	D013881
fluvoxamine	thioridazine	3	1	true	positive	The effect of fluvoxamine (25 mg b.i.d. for one week) on thioridazine steady-state concentration was evaluated in ten male inpatients with schizophrenia.  Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased 3-fold following coadministration of fluvoxamine.  Fluvoxamine and thioridazine should not be coadministered.  		42355	10502	D016666	D013881
fluvoxamine	thioridazine	3	1	true	positive	The effect of fluvoxamine (25 mg b.i.d. for one week) on thioridazine steady-state concentration was evaluated in ten male inpatients with schizophrenia.  Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased 3-fold following coadministration of fluvoxamine.  Fluvoxamine and thioridazine should not be coadministered.  		42355	10502	D016666	D013881
fluvoxamine	thioridazine	3	2	true	positive	Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased 3-fold following coadministration of fluvoxamine.  Fluvoxamine and thioridazine should not be coadministered.  		42355	10502	D016666	D013881
fluvoxamine	thioridazine	3	2	true	positive	Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased 3-fold following coadministration of fluvoxamine.  Fluvoxamine and thioridazine should not be coadministered.  		42355	10502	D016666	D013881
fluvoxamine	thioridazine	3	3	false	none	Fluvoxamine and thioridazine should not be coadministered.  		42355	10502	D016666	D013881
fluvoxamine	thioridazine	3	3	false	none	Fluvoxamine and thioridazine should not be coadministered.  		42355	10502	D016666	D013881
fluvoxamine	mesoridazine	1	2	false	none	The effect of fluvoxamine (25 mg b.i.d. for one week) on thioridazine steady-state concentration was evaluated in ten male inpatients with schizophrenia.  Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased 3-fold following coadministration of fluvoxamine.  		42355	6779	D016666	6779
fluvoxamine	mesoridazine	1	2	false	none	The effect of fluvoxamine (25 mg b.i.d. for one week) on thioridazine steady-state concentration was evaluated in ten male inpatients with schizophrenia.  Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased 3-fold following coadministration of fluvoxamine.  		42355	6779	D016666	6779
fluvoxamine	mesoridazine	2	2	false	none	Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased 3-fold following coadministration of fluvoxamine.  		42355	6779	D016666	6779
fluvoxamine	mesoridazine	2	2	false	none	Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased 3-fold following coadministration of fluvoxamine.  		42355	6779	D016666	6779
fluvoxamine	mesoridazine	3	2	false	none	Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased 3-fold following coadministration of fluvoxamine.  Fluvoxamine and thioridazine should not be coadministered.  		42355	6779	D016666	6779
fluvoxamine	mesoridazine	3	2	false	none	Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased 3-fold following coadministration of fluvoxamine.  Fluvoxamine and thioridazine should not be coadministered.  		42355	6779	D016666	6779
fluvoxamine	Fluvoxamine	1	1	false	none	The effect of fluvoxamine (25 mg b.i.d. for one week) on thioridazine steady-state concentration was evaluated in ten male inpatients with schizophrenia.  		D016666	D016666
fluvoxamine	Fluvoxamine	1	2	false	none	The effect of fluvoxamine (25 mg b.i.d. for one week) on thioridazine steady-state concentration was evaluated in ten male inpatients with schizophrenia.  Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased 3-fold following coadministration of fluvoxamine.  		D016666	D016666
fluvoxamine	Fluvoxamine	1	3	false	none	The effect of fluvoxamine (25 mg b.i.d. for one week) on thioridazine steady-state concentration was evaluated in ten male inpatients with schizophrenia.  Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased 3-fold following coadministration of fluvoxamine.  Fluvoxamine and thioridazine should not be coadministered.  		D016666	D016666
fluvoxamine	Fluvoxamine	2	1	false	none	The effect of fluvoxamine (25 mg b.i.d. for one week) on thioridazine steady-state concentration was evaluated in ten male inpatients with schizophrenia.  Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased 3-fold following coadministration of fluvoxamine.  		D016666	D016666
fluvoxamine	Fluvoxamine	2	2	false	none	Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased 3-fold following coadministration of fluvoxamine.  		D016666	D016666
fluvoxamine	Fluvoxamine	2	3	false	none	Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased 3-fold following coadministration of fluvoxamine.  Fluvoxamine and thioridazine should not be coadministered.  		D016666	D016666
fluvoxamine	Fluvoxamine	3	1	false	none	The effect of fluvoxamine (25 mg b.i.d. for one week) on thioridazine steady-state concentration was evaluated in ten male inpatients with schizophrenia.  Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased 3-fold following coadministration of fluvoxamine.  Fluvoxamine and thioridazine should not be coadministered.  		D016666	D016666
fluvoxamine	Fluvoxamine	3	2	false	none	Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased 3-fold following coadministration of fluvoxamine.  Fluvoxamine and thioridazine should not be coadministered.  		D016666	D016666
fluvoxamine	Fluvoxamine	3	3	false	none	Fluvoxamine and thioridazine should not be coadministered.  		D016666	D016666
sulforidazine	thioridazine	2	1	false	none	The effect of fluvoxamine (25 mg b.i.d. for one week) on thioridazine steady-state concentration was evaluated in ten male inpatients with schizophrenia.  Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased 3-fold following coadministration of fluvoxamine.  		none	10502	C040634	D013881
sulforidazine	thioridazine	2	1	false	none	The effect of fluvoxamine (25 mg b.i.d. for one week) on thioridazine steady-state concentration was evaluated in ten male inpatients with schizophrenia.  Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased 3-fold following coadministration of fluvoxamine.  		none	10502	C040634	D013881
sulforidazine	thioridazine	2	2	false	none	Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased 3-fold following coadministration of fluvoxamine.  		none	10502	C040634	D013881
sulforidazine	thioridazine	2	2	false	none	Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased 3-fold following coadministration of fluvoxamine.  		none	10502	C040634	D013881
sulforidazine	thioridazine	2	3	false	none	Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased 3-fold following coadministration of fluvoxamine.  Fluvoxamine and thioridazine should not be coadministered.  		none	10502	C040634	D013881
sulforidazine	thioridazine	2	3	false	none	Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased 3-fold following coadministration of fluvoxamine.  Fluvoxamine and thioridazine should not be coadministered.  		none	10502	C040634	D013881
sulforidazine	mesoridazine	2	2	false	none	Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased 3-fold following coadministration of fluvoxamine.  		none	6779	C040634	6779
sulforidazine	mesoridazine	2	2	false	none	Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased 3-fold following coadministration of fluvoxamine.  		none	6779	C040634	6779
sulforidazine	Fluvoxamine	2	1	false	none	The effect of fluvoxamine (25 mg b.i.d. for one week) on thioridazine steady-state concentration was evaluated in ten male inpatients with schizophrenia.  Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased 3-fold following coadministration of fluvoxamine.  		none	42355	C040634	D016666
sulforidazine	Fluvoxamine	2	1	false	none	The effect of fluvoxamine (25 mg b.i.d. for one week) on thioridazine steady-state concentration was evaluated in ten male inpatients with schizophrenia.  Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased 3-fold following coadministration of fluvoxamine.  		none	42355	C040634	D016666
sulforidazine	Fluvoxamine	2	2	false	none	Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased 3-fold following coadministration of fluvoxamine.  		none	42355	C040634	D016666
sulforidazine	Fluvoxamine	2	2	false	none	Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased 3-fold following coadministration of fluvoxamine.  		none	42355	C040634	D016666
sulforidazine	Fluvoxamine	2	3	false	none	Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased 3-fold following coadministration of fluvoxamine.  Fluvoxamine and thioridazine should not be coadministered.  		none	42355	C040634	D016666
sulforidazine	Fluvoxamine	2	3	false	none	Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased 3-fold following coadministration of fluvoxamine.  Fluvoxamine and thioridazine should not be coadministered.  		none	42355	C040634	D016666
thioridazine	mesoridazine	1	2	false	none	The effect of fluvoxamine (25 mg b.i.d. for one week) on thioridazine steady-state concentration was evaluated in ten male inpatients with schizophrenia.  Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased 3-fold following coadministration of fluvoxamine.  		10502	6779	D013881	6779
thioridazine	mesoridazine	1	2	false	none	The effect of fluvoxamine (25 mg b.i.d. for one week) on thioridazine steady-state concentration was evaluated in ten male inpatients with schizophrenia.  Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased 3-fold following coadministration of fluvoxamine.  		10502	6779	D013881	6779
thioridazine	mesoridazine	2	2	false	none	Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased 3-fold following coadministration of fluvoxamine.  		10502	6779	D013881	6779
thioridazine	mesoridazine	2	2	false	none	Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased 3-fold following coadministration of fluvoxamine.  		10502	6779	D013881	6779
thioridazine	mesoridazine	3	2	false	none	Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased 3-fold following coadministration of fluvoxamine.  Fluvoxamine and thioridazine should not be coadministered.  		10502	6779	D013881	6779
thioridazine	mesoridazine	3	2	false	none	Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased 3-fold following coadministration of fluvoxamine.  Fluvoxamine and thioridazine should not be coadministered.  		10502	6779	D013881	6779
thioridazine	Fluvoxamine	1	1	false	none	The effect of fluvoxamine (25 mg b.i.d. for one week) on thioridazine steady-state concentration was evaluated in ten male inpatients with schizophrenia.  		10502	42355	D013881	D016666
thioridazine	Fluvoxamine	1	1	false	none	The effect of fluvoxamine (25 mg b.i.d. for one week) on thioridazine steady-state concentration was evaluated in ten male inpatients with schizophrenia.  		10502	42355	D013881	D016666
thioridazine	Fluvoxamine	1	2	true	positive	The effect of fluvoxamine (25 mg b.i.d. for one week) on thioridazine steady-state concentration was evaluated in ten male inpatients with schizophrenia.  Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased 3-fold following coadministration of fluvoxamine.  		10502	42355	D013881	D016666
thioridazine	Fluvoxamine	1	2	true	positive	The effect of fluvoxamine (25 mg b.i.d. for one week) on thioridazine steady-state concentration was evaluated in ten male inpatients with schizophrenia.  Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased 3-fold following coadministration of fluvoxamine.  		10502	42355	D013881	D016666
thioridazine	Fluvoxamine	1	3	true	positive	The effect of fluvoxamine (25 mg b.i.d. for one week) on thioridazine steady-state concentration was evaluated in ten male inpatients with schizophrenia.  Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased 3-fold following coadministration of fluvoxamine.  Fluvoxamine and thioridazine should not be coadministered.  		10502	42355	D013881	D016666
thioridazine	Fluvoxamine	1	3	true	positive	The effect of fluvoxamine (25 mg b.i.d. for one week) on thioridazine steady-state concentration was evaluated in ten male inpatients with schizophrenia.  Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased 3-fold following coadministration of fluvoxamine.  Fluvoxamine and thioridazine should not be coadministered.  		10502	42355	D013881	D016666
thioridazine	Fluvoxamine	2	1	true	positive	The effect of fluvoxamine (25 mg b.i.d. for one week) on thioridazine steady-state concentration was evaluated in ten male inpatients with schizophrenia.  Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased 3-fold following coadministration of fluvoxamine.  		10502	42355	D013881	D016666
thioridazine	Fluvoxamine	2	1	true	positive	The effect of fluvoxamine (25 mg b.i.d. for one week) on thioridazine steady-state concentration was evaluated in ten male inpatients with schizophrenia.  Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased 3-fold following coadministration of fluvoxamine.  		10502	42355	D013881	D016666
thioridazine	Fluvoxamine	2	2	true	positive	Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased 3-fold following coadministration of fluvoxamine.  		10502	42355	D013881	D016666
thioridazine	Fluvoxamine	2	2	true	positive	Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased 3-fold following coadministration of fluvoxamine.  		10502	42355	D013881	D016666
thioridazine	Fluvoxamine	2	3	true	positive	Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased 3-fold following coadministration of fluvoxamine.  Fluvoxamine and thioridazine should not be coadministered.  		10502	42355	D013881	D016666
thioridazine	Fluvoxamine	2	3	true	positive	Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased 3-fold following coadministration of fluvoxamine.  Fluvoxamine and thioridazine should not be coadministered.  		10502	42355	D013881	D016666
thioridazine	Fluvoxamine	3	1	true	positive	The effect of fluvoxamine (25 mg b.i.d. for one week) on thioridazine steady-state concentration was evaluated in ten male inpatients with schizophrenia.  Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased 3-fold following coadministration of fluvoxamine.  Fluvoxamine and thioridazine should not be coadministered.  		10502	42355	D013881	D016666
thioridazine	Fluvoxamine	3	1	true	positive	The effect of fluvoxamine (25 mg b.i.d. for one week) on thioridazine steady-state concentration was evaluated in ten male inpatients with schizophrenia.  Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased 3-fold following coadministration of fluvoxamine.  Fluvoxamine and thioridazine should not be coadministered.  		10502	42355	D013881	D016666
thioridazine	Fluvoxamine	3	2	true	positive	Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased 3-fold following coadministration of fluvoxamine.  Fluvoxamine and thioridazine should not be coadministered.  		10502	42355	D013881	D016666
thioridazine	Fluvoxamine	3	2	true	positive	Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased 3-fold following coadministration of fluvoxamine.  Fluvoxamine and thioridazine should not be coadministered.  		10502	42355	D013881	D016666
thioridazine	Fluvoxamine	3	3	false	none	Fluvoxamine and thioridazine should not be coadministered.  		10502	42355	D013881	D016666
thioridazine	Fluvoxamine	3	3	false	none	Fluvoxamine and thioridazine should not be coadministered.  		10502	42355	D013881	D016666
mesoridazine	Fluvoxamine	2	1	false	none	The effect of fluvoxamine (25 mg b.i.d. for one week) on thioridazine steady-state concentration was evaluated in ten male inpatients with schizophrenia.  Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased 3-fold following coadministration of fluvoxamine.  		6779	42355	6779	D016666
mesoridazine	Fluvoxamine	2	1	false	none	The effect of fluvoxamine (25 mg b.i.d. for one week) on thioridazine steady-state concentration was evaluated in ten male inpatients with schizophrenia.  Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased 3-fold following coadministration of fluvoxamine.  		6779	42355	6779	D016666
mesoridazine	Fluvoxamine	2	2	false	none	Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased 3-fold following coadministration of fluvoxamine.  		6779	42355	6779	D016666
mesoridazine	Fluvoxamine	2	2	false	none	Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased 3-fold following coadministration of fluvoxamine.  		6779	42355	6779	D016666
mesoridazine	Fluvoxamine	2	3	false	none	Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased 3-fold following coadministration of fluvoxamine.  Fluvoxamine and thioridazine should not be coadministered.  		6779	42355	6779	D016666
mesoridazine	Fluvoxamine	2	3	false	none	Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased 3-fold following coadministration of fluvoxamine.  Fluvoxamine and thioridazine should not be coadministered.  		6779	42355	6779	D016666
